Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Recruiting NCT07362017

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Conditions: Moderate-to-severe Chronic Plaque Psoriasis

Sex: All

Ages: 18 Years – 65 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 300

Sponsor: Vanda Pharmaceuticals

Location: Vanda Investigational Site Glendale Arizona

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Inclusion Criteria: * Male and female subjects aged 18-65 years, inclusive * BMI \>18 and \

Interested in this study? View the official listing for contact and enrollment details.

Source: ClinicalTrials.gov (NCT07362017). StuddyBuddy aggregates publicly available trial information.